Non-diagonal open spin-1/2 XXZ quantum chains by separation of variables: Complete spectrum and matrix elements of some quasi-local operators

The integrable quantum models, associated to the transfer matrices of the 6-vertex reflection algebra for spin 1/2 representations, are studied in this paper. In the framework of Sklyanin's quantum separation of variables (SOV), we provide the complete characterization of the eigenvalues and eigenstates of the transfer matrix and the proof of the simplicity of the transfer matrix spectrum. Moreover, we use these integrable quantum models as further key examples for which to develop a method in the SOV framework to compute matrix elements of local operators. This method has been introduced first in [1] and then used also in [2], it is based on the resolution of the quantum inverse problem (i.e. the reconstruction of all local operators in terms of the quantum separate variables) plus the computation of the action of separate covectors on separate vectors. In particular, for these integrable quantum models, which in the homogeneous limit reproduce the open spin-1/2 XXZ quantum chains with non-diagonal boundary conditions, we have obtained the SOV-reconstructions for a class of quasi-local operators and determinant formulae for the covector-vector actions. As consequence of these findings we provide one determinant formulae for the matrix elements of this class of reconstructed quasi-local operators on transfer matrix eigenstates.Comment: 40 pages. Minor modifications in the text and some notations and some more reference adde

Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study

Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital, Prato, ItalyBackground: The aim of this study was to evaluate the proportion of patients with ankylosing spondylitis maintaining clinical remission after reduction of their subcutaneous etanercept dose to 50 mg every other week compared with that in patients receiving etanercept 50 mg weekly.Methods: In the first phase of this randomized, prospective, follow-up study, all biologic-naïve patients identified between January 2005 and December 2009 as satisfying the modified New York clinical criteria for ankylosing spondylitis treated with etanercept 50 mg weekly were evaluated for disease remission in January 2010. In the second phase, patients meeting the criteria for remission were randomized to receive subcutaneous etanercept as either 50 mg weekly or 50 mg every other week. The randomization allocation was 1:1. Remission was defined as Bath Ankylosing Spondylitis Disease Activity Index < 4, no extra-axial manifestations of peripheral arthritis, dactylitis, tenosynovitis, or iridocyclitis, and normal acute-phase reactants. The patients were assessed at baseline, at weeks 4 and 12, and every 12 weeks thereafter. The last visit constituted the end of the follow-up.Results: During the first phase, 78 patients with ankylosing spondylitis (57 males and 21 females, median age 38 years, median disease duration 12 years) were recruited. In January 2010, after a mean follow-up of 25 ± 11 months, 43 (55.1%) patients achieving clinical remission were randomized to one of the two treatment arms. Twenty-two patients received etanercept 50 mg every other week (group 1) and 21 received etanercept 50 mg weekly (group 2). At the end of follow-up, 19 of 22 (86.3%) subjects in group 1 and 19 of 21 (90.4%) in group 2 were still in remission, with no significant difference between the two groups. The mean follow-up duration in group 1 and group 2 was 22 ± 1 months and 21 ± 1.6 months, respectively.Conclusion: Remission of ankylosing spondylitis is possible in at least 50% of patients treated with etanercept 50 mg weekly. After halving of the etanercept dose, remission is maintained in a high percentage of patients during long-term follow-up, with important economic implications.Keywords: ankylosing spondylitis, anti-tumor necrosis factor, etanercept, remission, dose reductio

Form factors of descendant operators in the massive Lee-Yang model

The form factors of the descendant operators in the massive Lee-Yang model are determined up to level 7. This is first done by exploiting the conserved quantities of the integrable theory to generate the solutions for the descendants starting from the lowest non-trivial solutions in each operator family. We then show that the operator space generated in this way, which is isomorphic to the conformal one, coincides, level by level, with that implied by the $S$-matrix through the form factor bootstrap. The solutions we determine satisfy asymptotic conditions carrying the information about the level that we conjecture to hold for all the operators of the model.Comment: 23 page

Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction

Acute ventricular dysfunction (AVD) is a complex condition with substantial morbidity and mortality, still featuring unique therapeutic challenges. Levosimendan is a calcium sensitizer and ATP-dependent potassium channel opener that was developed as an inodilating drug for the treatment of acute heart failure and cardiogenic shock. Differently from other more widely used inotropic agents, levosimendan has some exclusive characteristics, in terms of mechanisms of action, pharmacodynamic profile, and haemodynamic effects. This may have important clinical implications. In particular, in patients with AVD or in patients with pre-existing severe ventricular impairment undergoing planned myocardial stress, the administration of levosimendan before the onset of overt symptoms or before cardiovascular therapeutic procedures may have the potential to bridge the patient through the critical phase. In this review, we will focus on the rationale, the existing experimental data, and the emerging clinical experience supporting an early, even preventive use of levosimendan in severe ventricular dysfunction, beyond its recognized indications

Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal

•The optimal antithrombotic regimen to be used in patients with AF and PCI or ACS is still debated.•Each of the six randomised controlled trials comparing double to triple therapy has limitations.•None was powered to assess differences between treatment arms in ischaemic event rates.•The contrasting results regarding ischaemic events within published meta-analyses can be explained by heterogeneity, incompleteness and varying definitions of stent thrombosis.•The overall reduced bleeding rates, but increased early definite and probable stent thrombosis rates with double versus triple antithrombotic therapy encourage consideration of triple therapy during the first weeks from PCI followed by double therapy